- ISIN
- US9013841070
- CUSIP
- 901384107
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- IPO Date
- Nov 3, 2021
Highlights
- Total Revenue (TTM)
- $48.37M
- Gross Profit (TTM)
- $27.26M
- EBITDA (TTM)
- -$52.72M
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
TSVT Performance Chart
Loading charts...
Returns By Period
2seventy bio, Inc.
- 1D
- —
- 1M
- —
- YTD
- —
- 6M
- —
- 1Y
- —
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.74%
- 1M
- 4.90%
- YTD
- 10.35%
- 6M
- 10.28%
- 1Y
- 26.52%
- 3Y*
- 20.83%
- 5Y*
- 12.30%
- 10Y*
- 13.66%
TSVT Monthly Returns History
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | -9.52% | -0.75% | 87.12% | 1.01% | 0.20% | 70.07% | |||||||
| 2024 | 20.37% | 1.17% | 2.88% | -14.77% | -7.24% | -8.98% | 22.60% | 3.18% | -3.08% | -8.05% | -8.06% | -26.32% | -31.15% |
| 2023 | 45.14% | -0.81% | -24.39% | -6.76% | 25.24% | -15.03% | -25.00% | -31.62% | -24.47% | -37.76% | -25.00% | 133.33% | -54.43% |
| 2022 | -27.16% | -20.51% | 14.96% | -21.10% | -7.88% | 6.45% | 9.02% | 2.36% | -1.22% | 9.14% | -1.32% | -40.20% | -63.44% |
| 2021 | 91.29% | -2.70% | 86.13% |
Benchmark Metrics
2seventy bio, Inc. has an annualized alpha of 7.89%, beta of 1.32, and R2 of 0.06 versus S&P 500 Index. Calculated based on daily prices since November 04, 2021.
- This stock participated in 166.58% of S&P 500 Index downside but only 57.03% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.06 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 7.89%
- Beta
- 1.32
- R²
- 0.06
- Upside Capture
- 57.03%
- Downside Capture
- 166.58%
Return for Risk
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for 2seventy bio, Inc. (TSVT) and compare them to S&P 500 Index.
Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the 2seventy bio, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the 2seventy bio, Inc. was 96.31%, occurring on Nov 21, 2023. The portfolio has not yet recovered.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2023 bear market2023 | -96.31%Nov 2023 | 2y 11d | — | 4y 6moNov 2021 - now |
Drawdown Indicators
| TSVT | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | — | -56.78% | — |
Max Drawdown (1Y)Largest decline over 1 year | — | -9.10% | — |
Max Drawdown (3Y)Largest decline over 3 years | — | -18.90% | — |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | — | -0.74% | — |
Average DrawdownAverage peak-to-trough decline | — | -10.72% | — |
Ulcer IndexDepth and duration of drawdowns from previous peaks | — | 1.97% | — |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of 2seventy bio, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how 2seventy bio, Inc. is priced in the market compared to other companies in the Drug Manufacturers - General industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with TSVT
Add 2seventy bio, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with TSVT